← Ishga qaytish
Ushbu ish iqtibos qilgan ishlar
16 ta ish
Ish: A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie, Andreas H. Diacon, Nosipho Ngubane +15
MaqolaOchiq kirish20207 iqtibosABIBedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Francesca Conradie, Tatevik R. Bagdasaryan, Borisov Se +25
MaqolaOchiq kirish20227 iqtibosABIA Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Andrew Nunn, Patrick Phillips, Sarah Meredith +16
MaqolaOchiq kirish20196 iqtibosABIDrug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei +35
Sharh maqolaOchiq kirish20204 iqtibosABIPrinciples for designing future regimens for multidrug-resistant tuberculosis
Grania Brigden, Bern-Thomas Nyang’wa, Philipp du Cros +9
MaqolaOchiq kirish20133 iqtibosABIFinancial burden for tuberculosis patients in low- and middle-income countries: a systematic review
Tadayuki Tanimura, Ernesto Jaramillo, Diana Weil +2
Sharh maqolaOchiq kirish20142 iqtibosABISafety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis
Ilse Tack, Asnake Yohannes Dumicho, Liesbet Ohler +6
MaqolaOchiq kirish20202 iqtibosABIPopulation pharmacokinetics and pharmacodynamics of investigational regimens’ drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial
Bern-Thomas Nyang’wa, Frank Kloprogge, David Moore +4
MaqolaOchiq kirish20212 iqtibosABI